Old Web
English
Sign In
Acemap
>
authorDetail
>
Conrad R. Lewanski
Conrad R. Lewanski
Imperial College London
Internal medicine
Mutant
Pathology
Oncology
Afatinib
2
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
P3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial)
2017
Journal of Thoracic Oncology
Sanjay Popat
Laura Hughes
Mary OBrien
T. Ahmad
Conrad R. Lewanski
Ulrike Dernedde
Petra Jankowska
Clive Mulatero
R. Shah
J. Hicks
Tom Geldart
Mathilda Cominos
Gill Gray
James Spicer
Karen Bell
Yenting Ngai
Allan Hackshaw
Show All
Source
Cite
Save
Citations (0)
Poster SessionP3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial): Topic: EGFR Clinical
2017
Journal of Thoracic Oncology
Sanjay Popat
Laura Hughes
Mary OBrien
T. Ahmad
Conrad R. Lewanski
Ulrike Dernedde
Petra Jankowska
Clive Mulatero
R. Shah
J. Hicks
Tom Geldart
Mathilda Cominos
Gill Gray
James Spicer
Karen Bell
Yenting Ngai
Allan Hackshaw
Show All
Source
Cite
Save
Citations (0)
1